Perbak Capital Partners LLP Purchases Shares of 34,077 Qiagen (NYSE:QGEN)

Perbak Capital Partners LLP bought a new position in Qiagen (NYSE:QGEN) during the fourth quarter, Holdings Channel reports. The firm bought 34,077 shares of the company’s stock, valued at approximately $1,517,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in QGEN. Northern Trust Corp increased its position in shares of Qiagen by 29.5% during the 4th quarter. Northern Trust Corp now owns 1,250,712 shares of the company’s stock valued at $55,694,000 after purchasing an additional 285,265 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Qiagen by 3.0% in the 4th quarter. The Manufacturers Life Insurance Company now owns 96,482 shares of the company’s stock worth $4,322,000 after purchasing an additional 2,832 shares during the period. Earnest Partners LLC raised its stake in Qiagen by 1.6% during the 4th quarter. Earnest Partners LLC now owns 4,002,489 shares of the company’s stock worth $178,231,000 after acquiring an additional 64,575 shares during the period. Susquehanna Fundamental Investments LLC purchased a new stake in Qiagen during the 4th quarter valued at approximately $5,645,000. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Qiagen by 23.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 142,794 shares of the company’s stock valued at $6,359,000 after purchasing an additional 27,518 shares in the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Wall Street Analysts Forecast Growth

QGEN has been the subject of several recent research reports. Robert W. Baird lifted their price objective on Qiagen from $42.00 to $43.00 and gave the company a “neutral” rating in a report on Monday, April 21st. Baird R W downgraded shares of Qiagen from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 19th. Redburn Atlantic cut shares of Qiagen from a “buy” rating to a “neutral” rating in a report on Friday, April 4th. Morgan Stanley reissued an “equal weight” rating and set a $46.67 target price (down previously from $48.61) on shares of Qiagen in a research note on Monday, January 6th. Finally, UBS Group cut their target price on shares of Qiagen from $50.00 to $48.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. Eight research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $47.83.

Qiagen Price Performance

QGEN opened at $42.49 on Tuesday. The company has a 50-day moving average of $40.02 and a 200-day moving average of $41.70. The company has a market capitalization of $9.45 billion, a P/E ratio of 118.31, a PEG ratio of 2.39 and a beta of 0.62. Qiagen has a 1-year low of $37.63 and a 1-year high of $49.30. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61.

Qiagen (NYSE:QGEN) last posted its earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. Equities analysts expect that Qiagen will post 2.26 EPS for the current fiscal year.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.